临床荟萃 ›› 2026, Vol. 41 ›› Issue (2): 160-163.doi: 10.3969/j.issn.1004-583X.2026.02.010

• 论著 • 上一篇    下一篇

不同亚型Castleman病2例报告并文献复习

杨晓玲1, 王占奎2()   

  1. 1.山东中医药大学,山东 济南 250355
    2.山东第一医科大学第一附属医院 风湿免疫科,山东 济南 250014
  • 收稿日期:2026-01-05 出版日期:2026-02-20 发布日期:2026-03-05
  • 通讯作者: 王占奎,Email:wzksdzhy@163.com

Two cases of distinct subtypes of Castleman disease: Case reports and literature review

Yang Xiaoling1, Wang Zhankui2()   

  1. 1. Shandong University of Traditional Chinese Medicine, Jinan 250355, China
    2. Department of Rheumatology and Immunology, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China
  • Received:2026-01-05 Online:2026-02-20 Published:2026-03-05
  • Contact: Wang Zhankui, Email:wzksdzhy@163.com

摘要:

目的 探讨Castleman病(Castleman disease,CD)透明血管型和浆细胞型的临床表现,提高对该病的认识。方法 回顾性分析2例不同亚型CD并结合文献探讨其诊疗要点。结果 病例1双侧腹股沟无痛性淋巴结肿大,经糖皮质激素联合托珠单抗治疗病情稳定;病例2全身淋巴结肿大、低热且IgE显著升高,经司妥昔单抗联合免疫调节治疗有效控制炎症。2例均存在诊断延误情况,需借助病理活检、IL-6检测及IgG4相关指标与淋巴瘤、IgG4相关疾病鉴别。结论 单中心型CD可通过手术或靶向IL-6通路治疗,多中心型则需长期多学科管理,注重抗感染和免疫调节。临床应结合病理与分子标志物精准分型,制定个体化治疗方案,同时关注复发风险与合并症管理。

关键词: Castleman病, 透明血管型, 浆细胞型, 巨淋巴结增生症

Abstract:

Objective To describe the clinical features of the hyaline-vascular and plasma-cell variants of Castleman disease (CD) and to raise clinical awareness of their presentation and management. Methods We retrospectively analyzed two cases of different CD subtypes and reviewed the relevant literature to summarize key diagnostic and therapeutic points. Results Case 1 presented with bilateral painless inguinal lymphadenopathy and achieved clinical stabilization with systemic glucocorticoids combined with tocilizumab. Case 2 had generalized lymphadenopathy, low-grade fever, and marked elevation of serum IgE; inflammatory activity was effectively controlled with siltuximab plus immunomodulatory therapy. Both patients experienced diagnostic delay. Definitive diagnosis required histopathological examination and ancillary testing, including interleukin-6 (IL-6) measurement and assessment of immunoglobulin G4 (IgG4)-related markers, to differentiate CD from lymphoma and IgG4-related disease. Conclusion Unicentric CD can often be cured by surgical excision or managed with therapies targeting the IL-6 pathway, while multicentric CD typically requires prolonged multidisciplinary care with emphasis on infection control and immune modulation. Precise subtyping based on pathology and molecular markers is essential to guide individualized treatment plans and to monitor for recurrence and comorbidities.

Key words: Castleman disease, Hyaline-vascular variant, Plasma-cell variant, Giant lymph node hyperplasia

中图分类号: